A study reported by Yasuhito Tanaka of the Nagoya City University Medical Department in Japan showed that the single nucleotide polymorphism (SNP) in the TLL1 gene is related to the occurrence and development of hepatocellular carcinoma after radical cure of hepatitis C virus infection. (Gastroenterology. 2017, 152: 1383-1394.) The researchers established different models by combining TLL1 gene mutation with other significant risk factors to predict the risk of liver cancer in patients with different degrees of liver fibrosis. TLL1 gene variants can be used to predict the risk of ጉበት ካንሰር in patients who have achieved a sustained virological response (SVR) in clinical practice. The study included Japanese patients who still suffered from liver cancer after interferon eradication of hepatitis C virus, and used genome-wide association analysis to identify which genes were mutated. The results showed that the TNP1 gene SNP rs17047200 on chromosome 4 is closely related to the occurrence of liver cancer after eradication of hepatitis C virus. There is no obvious linkage disequilibrium between other SNPs and rs17047200, and no more promising SNPs have been found in the exons and promoter regions of TLL1. Tanaka commented: “The mutant genes of liver cancer caused by hepatitis C virus include MICA and DEPDC5, which is very different from our test results.” In a multivariate analysis, the AT / TT base pairing of rs17047200 may lead to a 78% increased risk of liver cancer (P = 0.008). In the group of patients with mild fibrosis, older age is an independent risk factor for liver cancer; in the group of severe fibrosis, postoperative alpha-fetoprotein level and low albumin level are also risk factors. In two groups of liver fibrosis rat models, the mRNA level of TLL1 has increased, but only one group of models of TLL1 mRNA level is consistent with the progress of liver fibrosis. The level of TLL1 mRNA in patients with chronic hepatitis C also increases as liver fibrosis worsens.
ታናካ አመልክቷል: "እነዚህ መረጃዎች በመጀመሪያ በቲኤልኤል1 / ቲኤል1 አገላለጽ እና በሄፕታይተስ ስቴሌት ሴል ማግበር ወይም በእንስሳት ወይም በብልቃጥ ውስጥ እና በሰዎች ውስጥ የሄፕታይተስ ፋይብሮሲስ እድገት መካከል ያለውን ግንኙነት ያሳያሉ (አምሳያው ከአልኮል ውጭ የሆነ ስቴቶሄፓታይተስ ጋር የተያያዘ የጉበት ካንሰር ነው)። የጉበት ፋይብሮሲስ ወይም ካንሰር አዲስ ዘዴን ግልጽ ማድረግ ይችል ይሆናል. በሽተኛው ለሄፐታይተስ ሲ ቫይረስ ሥር ነቀል ሕክምና ከተቀበለ እና SVR ካገኘ በኋላ፣ ከTLL1 SNP ጋር የተገናኙ ሙከራዎች የጉበት ካንሰርን የሚያሰቃዩ ሰዎችን ለመለየት ጥቅም ላይ ሊውሉ ይችላሉ። TLL1 SNP ከዕድሜ, ከፋይብሮሲስ ዲግሪ, ከፍ ያለ የአልፋ-ፌቶፕሮቲን መጠን እና ሌሎች አደገኛ ሁኔታዎች ጥምረት ከ SVR በኋላ የጉበት ካንሰርን አደጋ ለመተንበይ ይረዳሉ. ምንም አይነት የኢንተርፌሮን የአፍ ህክምና እቅድ ከቀጥታ ከሚሰራ የፀረ-ቫይረስ መድሃኒት ህክምና ጋር ተዳምሮ በበለጸጉ ሀገራት ውስጥ መደበኛ የፀረ-ሄፐታይተስ ሲ ቫይረስ ህክምና እየሆነ ነው። ነገር ግን፣ ከኢንተርፌሮን ነፃ የሆነ SVR ከታከመ በኋላ የTLL1 ሚውቴሽን ከጉበት ካንሰር መከሰት ጋር የተያያዘ መሆኑን ለመገምገም አሁንም ተጨማሪ ምርምር ያስፈልጋል።
